Formula of drug for treating coronary heart disease and angina pectoris and application of formula

Abstract

The invention discloses a drug composition for treating the coronary heart disease and the angina pectoris. The drug composition is prepared by extracting and processing raw typha pollen, rhizoma pinellinae praeparata, the root of red-rooted salvia, dried tangerine or orange peel, radix pseudoginseng, radix polygonum multiflorum preparata, kelp, ligusticum wallichii, rhizoma alismatis, the fruit of Chinese wolfberry, semen cassiae torae and raw hawthorn as raw material drugs. The composition has the effects of activating blood and reducing phlegm, and descending turbid and relieving pain, and is used for treating chest stuffiness and pains caused by phlegm and blood stasis, and symptoms such as chest pains, chest distress and suffocation, palpitation and shortness of breath, limb heaviness and fat body shape of the coronary heart disease and the angina pectoris.

Description

technical field [0001] The invention relates to a traditional Chinese medicine composition, in particular to a medicinal composition for treating angina pectoris of coronary heart disease. Background technique [0002] Cardiovascular disease is a clinically important common and frequently-occurring disease. Nearly a quarter of the world's population is threatened by cardiovascular and related diseases. It is a hot topic in medical research. In the treatment of cardiovascular diseases in Western medicine, nitrates, calcium antagonists, β-blockers and angiotensin converting enzyme inhibitors (ACEI) are the most effective drugs that directly target the pathogenesis in reducing the mortality of coronary heart disease. However, in recent years, there has been much controversy over the therapeutic effects of nitrates, especially calcium antagonists (short-acting and long-acting). The data shows that in addition to the contraindications of the name, this large class of drugs also ...

AI Technical Summary

Problems solved by technology

Similarly, the efficacy of antiplatelet drugs is unsatisfactory, the selection and application of antithrombin drugs are chaotic, and individual responses to treatment vary greatly. The fatal reaction of secondary bleeding makes it difficult to maintain the ideal anticoagulant strength and affect the curative effect. Thrombin directly Long-term benefits of inhibitors yet to be recognized